What is the connection between PMOS and insulin resistance?

Insulin resistance is at the center of PMOS for the majority of women who have it. When cells become less responsive to insulin, the body compensates by producing more. That elevated insulin then signals the ovaries to produce more androgens than they should, and it is those elevated androgens that drive many of the most visible and disruptive symptoms of the condition: irregular cycles, acne, excess hair growth, difficulty maintaining stable weight, and energy instability. Understanding this mechanism is one of the most clarifying things a woman with PMOS can do, because it explains why the condition affects so many parts of the body at once.

What insulin resistance actually is

Insulin is a hormone produced by the pancreas that helps cells absorb glucose from the bloodstream for energy. In a body with healthy insulin sensitivity, cells respond readily to insulin's signal and the pancreas produces only as much as is needed. In a body with insulin resistance, cells respond sluggishly, and the pancreas compensates by producing more insulin to achieve the same effect.

The Mayo Clinic describes insulin resistance as a condition in which cells in your muscles, fat, and liver do not respond well to insulin and cannot easily take up glucose from the blood. Over time, if the pancreas cannot keep up with the demand, blood sugar levels begin to rise. For women with PMOS, the elevated insulin itself, before blood sugar becomes dysregulated, is already creating hormonal effects throughout the body.

How insulin resistance drives PMOS symptoms

The connection between elevated insulin and androgen production is the central mechanism of PMOS for most women. High insulin levels signal the ovaries and adrenal glands to produce more androgens, including testosterone. In women, testosterone at elevated levels drives acne, excess facial and body hair, hair thinning at the scalp, and disrupted ovulation.

Disrupted ovulation means follicles that begin to develop do not complete the maturation process. They arrest at an intermediate stage. Multiple arrested follicles on ultrasound is what historically generated the term "polycystic," even though these follicles are not cysts in any pathological sense. They are the downstream signature of the hormonal disruption, not its cause.

The American Journal of Managed Care, in its coverage of the PMOS consensus, noted that recognizing the condition as polyendocrine acknowledges that multiple interacting hormonal disturbances, including insulin and neuroendocrine hormones, are involved, rather than treating it as an isolated ovarian disorder. This framing opens the door for metabolic interventions to be prioritized alongside or before reproductive management.

"Hormones are not separate from the rest of your system."

— Dr. Samantha Ess, ND, Naturopathic Doctor specializing in hormone health and fertility

Why insulin resistance in PMOS is not only a weight issue

One of the most persistent misunderstandings about PMOS is that insulin resistance is a consequence of excess weight and would resolve with weight loss. Research has consistently shown that this is not true. Insulin resistance in PMOS is present in lean women as well as in women who are overweight. It is a feature of the underlying endocrine condition, not simply a lifestyle consequence.

According to STAT News, researchers involved in the renaming process have described insulin resistance as the engine of PMOS for most women who have it. The elevated insulin that results from that resistance is what confuses the ovary to make too much testosterone, driving the visible symptoms women experience. This means that addressing insulin sensitivity, through nutrition, movement, and where appropriate targeted supplementation, is a metabolic intervention with reproductive and hormonal consequences, not simply a weight management strategy.

The long-term metabolic risks of unaddressed PMOS

Because PMOS involves chronic insulin dysregulation and elevated androgen levels, it carries long-term metabolic health risks that extend well beyond reproductive concerns. The Lancet consensus paper documents that the condition is associated with increased risks of impaired glucose tolerance, type 2 diabetes, fatty liver disease, hypertension, dyslipidemia, cardiovascular disease, and sleep apnea.

These risks do not disappear at menopause. Research indicates that the metabolic features of PMOS persist after the reproductive years end. Women with PMOS reach menopause on average about two years later than women without the condition, according to current research on PMOS and the menopausal transition, but the underlying metabolic condition continues.

This is why the PMOS name change is not only about reproductive medicine. Naming the condition as metabolic creates the clinical mandate for ongoing metabolic monitoring, cardiovascular risk assessment, and comprehensive long-term care that has often been absent under the reproductive-only frame of PCOS.

"Birth control impacts the gut. The gut impacts the hormones. You can just see this cascading result."

— Dr. Samantha Ess, ND, Naturopathic Doctor specializing in hormone health and fertility

What the metabolic framing means for understanding your symptoms

For women living with PMOS, understanding insulin resistance as the central driver reframes the symptom picture in a clarifying way. Fatigue after meals is not random. It reflects the energy dysregulation that occurs when glucose uptake is inefficient. Skin changes, including acne and skin tags, reflect the androgen elevation that elevated insulin drives. Difficulty maintaining stable weight despite a reasonable diet reflects the metabolic disruption at the root of the condition. Mood instability and brain fog reflect the neurological effects of both insulin dysregulation and elevated androgens.

None of these symptoms exist in isolation. They are expressions of the same underlying metabolic and endocrine disruption. Understanding that connection does not make the symptoms less difficult to live with, but it does make them more legible, and it makes the path toward addressing them more coherent.

As Dr. Samantha Ess, ND observes: "Progesterone is low, so they put me on progesterone. But why is progesterone low? That's telling us that something's not optimal." The metabolic framing of PMOS is exactly this kind of upstream thinking applied at a systemic level. The question is not only what symptoms to manage, but what is driving them.

What a metabolically-informed approach to PMOS looks like

A metabolically-informed approach to PMOS starts with assessing insulin sensitivity directly, not just reproductive hormone panels. This means asking your provider for fasting glucose, fasting insulin, HOMA-IR, a lipid panel, and blood pressure assessment alongside any hormonal workup. These are the metabolic markers that paint the most accurate picture of what is driving the condition.

Lifestyle interventions with the strongest evidence base for improving insulin sensitivity include reducing ultra-processed foods and added sugars, increasing dietary fiber, regular resistance training, and prioritizing sleep. Each of these has documented effects on insulin sensitivity that translate to downstream hormonal improvements.

For more on the name change and its broader implications for women's health, see our guides on what PMOS is and why PCOS just got renamed and how the name change will affect diagnosis and treatment.

Frequently asked questions

What is insulin resistance and how does it relate to PMOS?

Insulin resistance means your cells respond sluggishly to insulin, so the pancreas produces more to compensate. In PMOS, elevated insulin signals the ovaries to overproduce androgens, which drives irregular cycles, acne, excess hair growth, and other symptoms. Insulin resistance is the central metabolic mechanism in most women with PMOS.

Can you have PMOS without being overweight?

Yes. Insulin resistance in PMOS is present in lean women as well as in women who carry excess weight. It is a feature of the underlying endocrine condition, not simply a consequence of body weight. This is one reason PMOS was so frequently missed: women who were thin were often told the condition was unlikely, when in fact it was driving their symptoms regardless of their size.

What tests assess insulin resistance in PMOS?

Fasting glucose, fasting insulin, and HOMA-IR (homeostatic model assessment of insulin resistance) are the most commonly used measures. A lipid panel and blood pressure reading are also useful for assessing the broader metabolic picture. Ask your healthcare provider to include these alongside any hormonal workup.

Does insulin resistance in PMOS go away on its own?

Insulin resistance in PMOS is a feature of the underlying endocrine condition and does not typically resolve without intervention. Lifestyle changes including dietary adjustments, regular movement, improved sleep, and stress management can meaningfully improve insulin sensitivity over time, and targeted supplementation may support that process in some women. Always work with your healthcare provider on a plan suited to your individual situation.

Does PMOS affect metabolic health after menopause?

Yes. The metabolic features of PMOS, including insulin dysregulation and elevated cardiovascular risk, do not resolve at menopause. Research indicates they persist into the postmenopausal years. This is one reason the PMOS renaming is significant: it creates the clinical mandate for ongoing metabolic monitoring throughout a woman's life, not just during the reproductive years.

What lifestyle changes most directly address insulin resistance in PMOS?

Reducing ultra-processed foods and added sugars, increasing dietary fiber and protein, engaging in regular resistance training, prioritizing seven to nine hours of sleep, and managing chronic stress are each independently documented to improve insulin sensitivity. These interventions work together and reinforce each other. Your healthcare provider can help you identify which changes are most impactful given your individual starting point.

† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider before starting any new supplement, especially during pregnancy, breastfeeding, or while managing a medical condition. Keep out of reach of children.